218595-25-6

Basic information

• Product Name: (S)-3-(Methoxymethyl)morpholine HCl
• Synonyms: (S)-3-(Methoxymethyl)morpholine HCl;(S)-3-(Methoxymethyl)morpholine;(S)-3-(MethoxyMethyl)Morpholine hydrochloride;(3S)-3-(methoxymethyl)morpholine
• CAS NO: 218595-25-6
• Molecular Formula: C₆H₁₃NO₂
• Molecular Weight: 168
• Mol File: 218595-25-6.mol

Chemical Properties

• Boiling Point: 180℃
• Flash Point: 63℃
• Appearance: /
• Density: 0.954
• Vapor Pressure: 0.929mmHg at 25°C
• Refractive Index: 1.415
• Storage Temp.: 2-8°C(protect from light)
• PKA: 8.28±0.40(Predicted)
• CAS DataBase Reference: (S)-3-(Methoxymethyl)morpholine HCl(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-3-(Methoxymethyl)morpholine HCl(218595-25-6)
• EPA Substance Registry System: (S)-3-(Methoxymethyl)morpholine HCl(218595-25-6)

Safety Data

• Hazardous Substances Data: 218595-25-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Synthesis:
(S)-3-(Methoxymethyl)morpholine HCl is used as a chiral building block for the production of pharmaceuticals and agrochemicals. Its unique structure and properties enable the creation of enantiomerically pure compounds, which are essential for the development of effective and safe medications.
Used in Organic Compound Synthesis:
In the field of organic chemistry, (S)-3-(Methoxymethyl)morpholine HCl is utilized as a versatile intermediate for the synthesis of various organic compounds. Its methoxymethyl group can be further modified or used as a protecting group, facilitating the synthesis of complex organic molecules.
Used in Material Development:
(S)-3-(Methoxymethyl)morpholine HCl is employed in the development of new materials, such as chiral catalysts, ligands, and chiral stationary phases for chromatography. Its unique properties contribute to the advancement of materials with specific applications in various industries.
Used in Medicinal Chemistry Research:
(S)-3-(Methoxymethyl)morpholine HCl is used as a research tool in medicinal chemistry to explore its potential as a precursor for the development of novel therapeutic agents. Its ability to form stable derivatives and its chiral nature make it an attractive candidate for the design of new drugs with improved efficacy and selectivity.

InChI:InChI=1/C6H13NO2/c1-8-4-6-5-9-3-2-7-6/h6-7H,2-5H2,1H3/t6-/m0/s1

Upstream product

• 101376-25-4 (S)-4-benzyl-3-(hydroxymethyl)morpholine 

Downstream Products

• 218785-45-6 (2R)-1-[3,5-bis-(trifluoromethyl)benzoyl]-2-(3,4-dimethylbenzyl)-4-[4-((3S)-3-methoxymethylmorpholino)-2-butynyl]piperazine 

Relevant articles and documents

Development of the First Generation of Disulfide-Based Subtype-Selective and Potent Covalent Pyruvate Dehydrogenase Kinase 1 (PDK1) Inhibitors

Pyruvate dehydrogenase kinases (PDKs) are overexpressed in most cancer cells and are responsible for aberrant glucose metabolism. We previously described bis(4-morpholinyl thiocarbonyl)-disulfide (JX06, 16) as the first covalent inhibitor of PDK1. Here, on the basis of the scaffold of 16, we identify two novel types of disulfide-based PDK1 inhibitors. The most potent analogue, 3a, effectively inhibits PDK1 both at the molecular (kinact/Ki = 4.17 × 103 M-1 s-1) and the cellular level (down to 0.1 μM). In contrast to 16, 3a is a potent and subtype-selective inhibitor of PDK1 with >40-fold selectivity for PDK2-4. 3a also significantly alters glucose metabolic pathways in A549 cells by decreasing ECAR and increasing ROS. Moreover, in the xenograft models, 3a shows significant antitumor activity with no negative effect to the mice weight. Collectively, these data demonstrate that 3a may be an excellent lead compound for the treatment of cancer as a first-generation subtype-selective and covalent PDK1 inhibitor.